Liangdong Sun

机构：Tongji University, Shanghai Pulmonary Hospital

发表论文 41 篇 · 总被引 2424 次 · h-index 15

代表论文

• Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing (2023 · Genome Medicine · 被引 399)
• Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies (2024 · Cell · 被引 188)
• Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer (2024 · Nature Genetics · 被引 145)
• Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial (2022 · BMC Medicine · 被引 68)
• Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study (2023 · Nature Communications · 被引 46)
• Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study (2024 · Signal Transduction and Targeted Therapy · 被引 35)